Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Prevention of BPD in Preterm Infants
NCT00931632Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- May 2013
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
A Phase 3 trial of nitric oxide in bronchopulmonary dysplasia (BPD), sponsored by Mallinckrodt Pharmaceuticals. Started Nov 2009; status: completed.
02
Drugs
nitric oxide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT00931632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931632.